Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.61 |
| ▸ | ANTXR2 | P58335 | 3/20 | 0.58 |
| ▸ | F11 | P03951 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.56 |
| ▸ | PDE5A | O76074 | 1/20 | 0.56 |
| ▸ | HMGCR | P04035 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.56 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8952214 | 0.97 | ANTXR2 (0.61) | PTPN1ANTXR2F11USP2CA1 | |
| SCHEMBL10177705 | 0.97 | ANTXR2 (0.61) | PTPN1ANTXR2F11USP2CA1 | |
| SCHEMBL12172394 | 0.97 | ANTXR2 (0.61) | PTPN1ANTXR2F11USP2CA1 | |
| SCHEMBL19038896 | 0.97 | ANTXR2 (0.61) | PTPN1ANTXR2F11USP2CA1 | |
| SCHEMBL2816580 | 0.97 | ANTXR2 (0.61) | PTPN1ANTXR2F11USP2CA1 | |
| SCHEMBL2814863 | 0.97 | ANTXR2 (0.61) | PTPN1ANTXR2F11USP2CA1 | |
| SCHEMBL1322250 | 0.97 | ANTXR2 (0.61) | PTPN1ANTXR2F11USP2CA1 | |
| SCHEMBL3785587 | 0.95 | PTPN1 (0.67) | PTPN1ANTXR2F11USP2CA1 | |
| SCHEMBL12326369 | 0.95 | PTPN1 (0.67) | PTPN1ANTXR2F11USP2CA1 | |
| SCHEMBL19479105 | 0.95 | PTPN1 (0.67) | PTPN1ANTXR2F11USP2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367641-B2 | Use of modified oligo-β-(1,3)-glucans for treating diseases of the immune system, oligo-β-(1,3)-glucan-(1,3)-mannose, oligo-β-(1,3)-glucan-(1,3)-mannitol and derivatives thereof, methods for preparing them and medicaments containing them | ASE & BIO (FR) | 2013-02-05 | — | — | US | disclosed |
| US-20100286388-A1 | USE OF MODIFIED OLIGO-B-(1,3)-GLUCANS FOR TREATING DISEASES OF THE IMMUNE SYSTEM, OLIGO-B- (1,3V-GLUCAN-(1,3)- MANNOSE, OLIGO-B-(1,3)-GLUCAN-(1,3)- MANNITOL AND DERIVATIVES THEREOF, METHODS FOR PREPARING THEM AND MEDICAMENTS CONTAINING THEM | ASE & BIO (FR) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286388-A1 | USE OF MODIFIED OLIGO-B-(1,3)-GLUCANS FOR TREATING DISEASES OF THE IMMUNE SYSTEM, OLIGO-B- (1,3V-GLUCAN-(1,3)- MANNOSE, OLIGO-B-(1,3)-GLUCAN-(1,3)- MANNITOL AND DERIVATIVES THEREOF, METHODS FOR PREPARING THEM AND MEDICAMENTS CONTAINING THEM | MAN2A1, MANBA, MAN2B1 | PTPN1 1285/4885ANTXR2 3941/4885F11 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.